844.50 USD
▲-18.76+1.65%
盘后 850.13 -0.43%
2026-07-31
市值
$52.43B
市盈率
30.57
EPS
26.21
股息率
—
52 周区间
631.47 – 953.58
成交量
264.38K
Beta
-0.02
目标价
1,079.55
52W 低 631.4752W 高 953.58
价格走势
公司简介
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system...